{
  "source": "PA-Notification-Vizimpro.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1262-7\nProgram Prior Authorization/Notification\nMedication Vizimpro® (dacomitinib)\nP&T Approval Date 11/2018, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nVizimpro® (dacomitinib) is a kinase inhibitor indicated for the first-line treatment of patients with\nmetastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)\nexon 19 deletion or exon 21 L858R substitution mutations. The National Cancer Comprehensive\nNetwork (NCCN) also recommends the use of Vizimpro as first-line or continuation of therapy\nfor recurrent, advanced, or metastatic NSCLC with EGFR S768I, L861Q, and/or G719X mutation\npositive tumors.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Vizimpro will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-small cell lung cancer (NSCLC)\n1. Initial Authorization\na. Vizimpro will be approved based on all of the following criteria:\n(1) Diagnosis of NSCLC\n-AND-\n(2) Disease is recurrent, advanced or metastatic\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(3) Disease is positive for one of the following EGFR mutations:\n(a) Exon 19 deletion\n(b) Exon 21 L858R substitution\n(c) S768I\n(d) L861Q\n(e) G719X\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vizimpro will be approved based on the following criterion:\n(1) Patient d",
    "(b) Exon 21 L858R substitution\n(c) S768I\n(d) L861Q\n(e) G719X\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vizimpro will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Vizimpro\ntherapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vizimpro [package insert]. Pfizer Labs: New York, NY; December 2020.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org. Accessed September 25, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Notification – Vizimpro (dacomitinib)\nChange Control\n11/2018 New program.\n11/2019 Annual review. Added NCCN recommended regimens criteria.\nUpdated references.\n11/2020 Annual review. Updated coverage criteria based on NCCN\nrecommendations. Updated background and references.\n11/2021 Annual review. Updated coverage criteria based on NCCN\nrecommendations. Updated background and references.\n11/2022 Annual review. Added coverage for EGFR S768I, L861Q, and G719X\nmutation positive tumors under coverage criteria for non-small cell lung\ncancer per NCCN guidelines. Up",
    "ackground and references.\n11/2022 Annual review. Added coverage for EGFR S768I, L861Q, and G719X\nmutation positive tumors under coverage criteria for non-small cell lung\ncancer per NCCN guidelines. Updated background, added state\nmandate, and updated references.\n11/2023 Annual review. Updated reference.\n11/2024 Annual review. No changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}